Results of Tabula Rasa HealthCare’s First Simulated Clinical Study on Proposed COVID-19 Treatments and Therapies is Published
Tabula Rasa HealthCare (TRHC) announced the publication of a study from its Precision Pharmacotherapy Research and Development Institute (PPRDI) in the Journal of Clinical Medicine. The research assesses the risk of adverse drug events (ADEs) when introducing COVID-19 repurposed drugs in frail older adults with polypharmacy. Using MedWise technology, the study found increased MedWise Risk Scores for participants, highlighting risks associated with drug-drug interactions and potential long QT syndrome. TRHC's findings reinforce the importance of their predictive tools in optimizing medication safety.
- Publication of significant research in a peer-reviewed journal.
- Validation of MedWise technology in assessing medication safety.
- Identification of at-risk patient subgroups for better healthcare outcomes.
- Increased MedWise Risk Scores indicate potential safety concerns among patients.
- Findings suggest that combining certain COVID-19 drugs may lead to serious health risks.
MOORESTOWN, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc® (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announces TRHC’s Precision Pharmacotherapy Research and Development Institute (PPRDI) published the research article, “Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy”, in the August 10, 2020 online edition of the Journal of Clinical Medicine. The article is a result of the first U.S. simulation study conducted in an outpatient setting to assess the estimated risk of adverse drug events (ADEs) with repurposed COVID-19 treatments.
In the study, TRHC’s PPRDI first utilized TRHC’s MedWise™ technology to determine each patient’s MedWise Risk Score™ (MRS), which is a predictive tool for adverse drug events (ADEs). Next, five repurposed COVID-19 drugs (or drug combinations) were added, one at a time, to patient drug regimens. The drug combinations included hydroxychloroquine, alone and in combination with azithromycin; chloroquine, alone and in combination with azithromycin; and lopinavir + ritonavir.
“The results of this study validate the science behind our MedWise technology,” states TRHC Chair and CEO Calvin H. Knowlton, Ph.D. “The cumulative multi-drug analysis of MedWise is an essential tool for the medical community to embrace when assessing the risk of introducing therapies that have not been proven in any other clinical setting.”
The study showed an increased MRS for a significant number of participants with all drugs (or drug combinations) due to drug-drug interactions competing for their metabolic pathway and the increased risk for drug-induced Long QT syndrome. Long QT syndrome is a disorder that can cause fast and chaotic heartbeats, triggering a sudden fainting spell, seizure, and in some cases, death.
“Our study confirms there is a safe way to examine the risks of adding new medications to an individual’s medication regimen, before they are prescribed the drug,” states TRHC’S PPRDI Chief Operating Officer Veronique Michaud, Ph.D. “We looked at the impact of these drugs on the total MedWise Risk Score and each of its components. The results showed which subgroups of patients are at increased risk of toxicity when exposed to one or another COVID-19 repurposed drug used off-label.”
About Tabula Rasa HealthCare
TRHC (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com.
About TRHC’s Precision Pharmacotherapy Research and Development Institute
TRHC’s PPRDI is committed to developing proprietary products, validation, and recognition by scientific and regulatory communities, improving patient outcomes, and reducing preventable healthcare utilization and costs. In 2020, the TRHC research pillar has 39 active research projects, 32 peer-reviewed publications in well-renowned journals, eight manuscripts accepted for publication, and two National Institute of Health research grants under review.
Forward-Looking Statement
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. These forward-looking statements include, among other things, our goals and expectations regarding the combined company and the integration of PW into TRHC, the expected synergies from the combined company and the expected financial and operating performance of TRHC following the completion of the acquisition. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the risk that we may not be able to achieve our expectations for the combined companies due to challenges in integration and inability to retain key employees; fluctuations in our financial results; the acceptance and use of our products and services by PACE organizations and pharmacies; the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; our ability to maintain relationships with a specified drug wholesaler; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; the requirements of being a public company; our ability to recognize the expected benefits from acquisitions on a timely basis or at all; and the other risk factors set forth from time to time in our filings with the Securities and Exchange Commission (“SEC”), including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 2, 2020, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website ir.trhc.com or upon request from our Investor Relations Department. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.
| TRHC Media Contact Amanda Bednar abednar@trhc.com T: (856) 912-5714 Dianne Semingson dsemingson@trhc.com T: (215) 870-0829 | Investors Frank Sparacino fsparacino@trhc.com T: (312) 451-2157 |
An infographic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/39f266a5-2e22-4c29-8ae7-d2d4d0ce75c4
FAQ
What does TRHC's recent study in the Journal of Clinical Medicine focus on?
What technology did TRHC use in their recent research?
What are the implications of TRHC's study findings?
What was the outcome of the study conducted by TRHC?
When was TRHC's study published?
